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One Health, One Virology
Esteemed Rector Magnificus, dear family, friends, colleagues, ladies and gentlemen,
I am honoured to stand here in front of you in the Aula of Wageningen 
University to present my inaugural lecture upon taking up the position of 
Special Professor of ‘Emerging and Zoonotic Viruses’. In this lecture I will 
talk about current approaches in this field of research and explain about my 
plans for research and education.
A virus outbreak wakeup call 
Let me take you back to the year 2003. On 12 March, the World Health 
Organisation (WHO) issued a worldwide alert about cases of atypical 
pneumonia caused, most likely, by a new infectious agent. Since mid-
February, cases of severe pneumonia had been reported in Hong Kong, 
Vietnam and the Guangdong province in China. Symptoms included an 
initial flu-like illness with rapid onset, followed by muscle pain and 
headache. Patients manifested a bilateral pneumonia, in some cases 
progressing to acute respiratory distress. The outbreak seemed to have 
started in Guangdong. China reported 305 cases of atypical pneumonia in 
this region in mid-February and five people died. Investigations into the 
cause of the outbreak had not yielded any clues yet. WHO recommended 
isolating patients with atypical pneumonia possibly related to these 
outbreaks and caring for them with barrier nursing techniques. WHO also 
recommended reporting any suspect cases to national health authorities. The 
situation worsened: Within a few days people returning to Toronto from 
Hong Kong showed symptoms of the disease. So just three days after the 
first global alert, WHO issued a heightened global health alert about the 
mysterious pneumonia, and added a case definition of the disease. In March 
and April, WHO and the Centers for Disease Control (CDC) in Atlanta, 
issued travel warnings. All non-essential travel to Hong Kong and 
Guangdong province in China should be postponed.
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The highly alarming situation I have just described is the SARS outbreak. 
Today SARS is still remembered as one of the most frightening disease 
outbreaks ever in humans. During the outbreak, and in subsequent years, 
much research was done to find the cause of the disease, to characterize the 
agent, and to clarify why it spread so quickly. 
The most likely index case of SARS was a 46-year-old man in Foshan. He 
had helped in a kitchen cooking wild meat. Shortly after, he developed a 
severe atypical pneumonia with headache and fever. The same symptoms 
were seen in dozens of people in the Guangzhou region. One of the patients 
was a fish trader who ran a stall on the market. He was treated in 
Guangzhou hospital where he infected more than 20 healthcare workers, 
including a young doctor. The doctor travelled to Hong Kong for his 
brother’s wedding. He stayed in the Metropole hotel where he fell ill and 
infected sixteen other guests and a visitor to the hotel. Some of these people 
travelled over the next few days to Canada and Singapore. This was the start 
of the intercontinental spread of the infectious disease.
Identifying the cause of this new disease was difficult back in 2003. First, a 
series of pathogens, including influenza and mycoplasma, seemed to be 
associated with disease cases. Eventually, Dr Malik Peiris and his team at the 
Pasteur Research Centre, University of Hong Kong cultured a virus on vero 
cells taken from respiratory tract samples and identified a coronavirus by 
electron microscopy. Peiris and his team neutralized the culture using 
antibody-positive serum from infected patients. That proved this virus was 
the cause of the disease. As soon as the virus was identified, specific 
diagnostic methods could be developed and targeted control strategies 
implemented. First of all, however, biosecurity measures were used to 
reduce the number of new cases. Isolation of symptomatic patients played a 
major role in the control of SARS. This was so effective because people 
infected with SARS showed symptoms near the start of their infectious 
period. Health authorities could therefore isolate most infected persons 
before they infected somebody else. On 5 July 2003, almost five months after 
the SARS outbreak started, WHO declared the world SARS-free.
The SARS outbreak had a huge negative impact on the economy and society. 
It created international anxiety due to its novelty, ease of transmission in 
certain settings, fast spread through jet travel and the extensive media 
coverage it received. Western media were blamed for focussing too much on 
the negative aspects. Their coverage made people more frightened of SARS 
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than they needed to be. Conferences in China were cancelled, and people 
postponed their travel. Direct economic losses due to SARS were 
estimated to be more than 40 billion dollars. 
Animal viruses often infect humans too
Almost 70% of all new infectious viruses in humans originate from 
animals. Viruses transmitted directly from vertebrate animals to humans 
are called zoonoses. SARS became a suspected zoonosis soon after the 
start of the outbreak. Many wild animals are traded on local markets in 
China. The authorities therefore tested these for SARS Coronavirus. The 
virus was soon isolated from masked palm civets (Paguma sp.) a forest 
animal hunted in China for its meat. SARS Coronavirus was believed to 
have crossed the species barrier from Asian palm civet to humans. Many 
of these animals were subsequently killed. Later on, SARS-like 
coronaviruses were detected in Chinese horseshoe bats and extensive 
research on genetic evolution, receptor binding and pathogenesis 
demonstrated that SARS-CoV most likely originated in bats through 
sequential recombinations. Masked palm civets appeared to be 
intermediate hosts of the virus.
Asian Palm Civet cat (Paradoxurus hermaphroditus) and Chinese Horseshoe bat (Rhinolophus 
ferrumequinum). © Francis Yap Photography - WordPress.com
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New approach needed 
The outbreak of SARS was a wake-up call for at least three main reasons: 
First of all, it showed that a new disease outbreak can spread very rapidly 
over the world due to increasing travel and people having frequent contacts. 
Increasing transports may have a similar effect in the case of foodborne 
infections and animal infectious diseases. Secondly, media attention, which 
now includes social media, may cause considerable worldwide anxiety as 
soon as the first cases of an outbreak are reported. Thirdly, new emerging 
disease outbreaks are complex and challenging events. Every pathogen has 
its own specific traits and interaction characteristics with the host. 
Transmission and spread strongly depend on people’s behaviour. Therefore 
right from the start, public health workers and researchers from different 
disciplines must work closely together to quickly control a new disease 
outbreak and effectively prevent new outbreaks of infection. This need for 
collaboration has led to the current One Health approach that I will now 
explain. 
One Health
The idea that human, animal and environmental health are linked can be 
traced back to ancient times. In his text “On Airs, Waters, and Places”, the 
Greek physician Hippocrates (460 – 370 BC) promoted the concept that 
public health depended on a clean environment.
In the 19th century, scientists developed a strong interest in linking human 
and veterinary medicine. Rudolf Virchow is probably the best-known 
example. With the start of cellular pathology, these scientists developed a 
form of comparative medicine based on the discovery of similar disease 
processes in humans and animals. 
Calvin Schwabe (1927-2006) seems to have coined the term “One Medicine”. 
Schwabe was an American veterinarian who wrote extensively about the 
relationship between animal and human diseases (Wilhelmsson et al. 2013). 
The interrelationship between human and animal health is a pillar of the 
“One Medicine” concept, and recent disease outbreaks like Bovine 
Spongiform Encephalopathy (BSE) have underlined its importance. 
Comparative pathology showed that the sheep disease scrapie and the 
human variant Creutzfeldt-Jacobs Disease (CJD) were similar. Initially, the 
risk for humans was unclear. Later, however, the BSE epidemic in cattle gave 
rise to several hundred variant CJD cases. Exposure to BSE is now thought to 
have been the cause. This outbreak led to European governments and the EU 
Wageningen University & Research | 7 
reconsidering who is the responsible authority for initiating and conducting 
risk assessment and management of diseases that affect both humans and 
animals. Ultimately, the BSE crisis created the conditions for establishing a 
joint European Food Safety Authority in 2002 (Budka 2011). It also 
highlighted the complexities of the food chain required for meat production 
and underlined the importance of considering health in a broader context. 
This broader so-called “One Health” approach was further embraced in 
about round 2004, when fears arose that the highly pathogenic H5N1 avian 
influenza could cause a pandemic. One Health recognizes that humans do 
not exist in isolation. Rather they are part of a larger whole, a living 
ecosystem in which each member’s activities affect the others. Whereas “One 
Medicine” historically implied links between veterinary and human 
medicine, One Health considers health as a whole: humans, animals, plants 
and environment they interact with. Nowadays the expression “One Health” 
has been adopted by many professionals: epidemiologists, physicians, 
veterinarians, wildlife specialists, and environmentalists. It is also used by 
many international organizations working on the control of zoonoses like 
the World Health Organisation (WHO), the Food and Agriculture 
Organisation (FAO) and the World Organisation for Animal Health (OIE). 
Hippocrates (460 – 370 before Christ), Rudolf Virchow (1821 – 1902) and Calvin Schwabe (1927 – 2006). 
Environmental Health, Comparative Medicine and One Medicine.
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One Health can be defined as ‘The collaborative effort of multiple health 
science professions, together with their related disciplines and institutions – 
working locally, nationally, and globally – to attain optimal health for 
people, domestic animals, wildlife, plants, and our environment’. Inevitably, 
it is important to study infectious agents that may cross species and 
environmental barriers to move between these compartments. 
One Health needed for Hepatitis E
Hepatitis E is a disease that can only be controlled effectively using a One 
Health approach. Hepatitis E is an inflammation of the liver caused by infection 
with the hepatitis E virus. Disease symptoms include jaundice, fatigue and 
nausea. This virus has at least five different genotypes. Genotype 3 is the 
predominant genotype in Europe and has a very high prevalence in domestic 
swine worldwide. Each year, about 133,000 new infections with hepatitis E 
virus occur in the Netherlands. The main cause of infection is the consumption 
of raw or undercooked pork. However, the virus can also be transmitted via 
blood donations. In healthy people, infections usually run a subclinical course, 
but people with underlying liver disease or a hampered immune system may 
develop severe disease symptoms. Especially patients who receive blood 
products can develop an acute and chronic liver disease that may be fatal. Solid 
One Health, ‘The collaborative effort of multiple health science professions, together with their related 
disciplines and institutions – working locally, nationally, and globally – to attain optimal health for 
people, domestic animals, wildlife, plants, and our environment’.
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organ transplant recipients who receive immunosuppressive drugs represent 
the majority of patients with chronic hepatitis E infection. In such cases, 
reduced administration of immunosuppressive drugs is often part of the 
clinical therapy and may lead to clearance of the hepatitis E infection. Antiviral 
therapy in the form of ribavirin monotherapy is the current treatment of choice 
for patients with chronic hepatitis E infection. About 85% of these patients 
show a sustained virological response.
The best way to control hepatitis E would be to eradicate the virus in the 
swine reservoir. However, that would be extremely difficult. The virus is 
highly contagious in pigs and can survive for a relatively long period in soil 
and water environments. Biosecurity and hygiene standards at farms would 
therefore have to be raised significantly. Moreover, as pigs suffer no 
symptoms, a vaccine to control the virus is not available. Pig farmers 
therefore have little incentive to combat hepatitis E infections. 
Recent studies show a rise in hepatitis E cases throughout Europe and in 
high-income countries outside Europe. The European Food Safety Authority 
(EFSA) acknowledged this several years ago and appointed a working group 
on hepatitis E virus in 2016. This working group, which I was a member of, 
published a scientific opinion on the public health risks of hepatitis E virus. 
They concluded that qualitative methods for detecting the virus should be 
developed together with more effective control measures. In the 
Netherlands, the Ministry of Health, Welfare and Sport commissioned the 
Health Council of the Netherlands to investigate the risk of hepatitis E virus 
contamination in blood products. The expert committee, which I was part of, 
concluded that testing for the virus in blood donations should be continued 
and that control measures in the food chain merited further research. 
At Wageningen Bioveterinary Research, we have worked on hepatitis E virus 
for more than 15 years. In 2009, Martijn Bouwknegt completed his PhD on 
hepatitis E virus infections in pigs, transmission dynamics and human 
exposure. His research demonstrated that domestic pigs are a true reservoir 
of hepatitis E virus, which may be transmitted to humans directly or 
indirectly from the pork production chain. The next PhD on the virus in our 
group was Alessandra Berto, who worked on culturing the hepatitis E virus 
and the feasibility of a vaccination strategy on pig farms. This research was 
part of the EU project VITAL on “Control of foodborne viruses in food 
supply chains”. A major breakthrough was the first ever culture of infectious 
hepatitis E virus from a ready-to-eat sausage. These research projects have 
contributed significantly to our understanding of hepatitis E virus 
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contaminations and the associated public health threats. However, several 
important research objectives remain, and so our work in this field 
continues. 
Preparing for the unknown
In 2015, the World Health Organisation produced a list of pathogens for 
research and development in public health emergency contexts. This list 
aims to clearly identify diseases that pose a public health risk because of 
their epidemic potential and for which countermeasures do not exist or are 
insufficient. This Blueprint list of priority diseases includes viruses like 
SARS-CoV and Ebola. In 2018, at the time of the second annual review, 
“Disease X” was added to this list. Disease X is the code name for an 
unknown pathogen, which may cause disease and potentially an epidemic 
in the future. It was added to the list of priority diseases as a “known 
unknown”. This addition acknowledged the fact that a new epidemic might 
be caused by an unknown pathogen. Therefore diagnostic and medical 
preparedness that is also relevant for an unknown pathogen should be 
sought as much as possible.
Food and Environmental Routes of Hepatitis E Virus Transmission.
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This WHO initiative clearly demonstrates the view of public health officials 
that more research is needed to better prepare us for unknown infectious 
diseases. Fortunately, as new pathogens with fresh diagnostic challenges 
have emerged in recent decades a molecular revolution in laboratory 
methods has also taken place. Several of these techniques target specific 
parts of virus genomes to detect and identify viruses. Development and 
implementation of these new molecular technologies have led to a 
tremendous increase in the success rates for virus discovery. I will now 
describe some of these extremely valuable molecular methods. 
Molecular detection and characterization methods
Polymerase chain reaction
Polymerase chain reaction (PCR) was the first diagnostic technique based 
on nucleic acids to be described. Now it is the most widely used targeted 
nucleic-acid-based method in virology. In the technique, nucleic acids from 
clinical samples are exposed to cycles of heating and cooling. This 
repeatedly melts the DNA, and every time this is followed by enzyme-
driven DNA replication. The result is high concentrations of specific DNA 
fragments. These can be used in DNA fingerprint analyses or sequencing 
that identifies viruses based on their genomic composition. Nucleic acid 
amplification and the subsequent sequencing of overlapping fragments are 
used to determine complete genome sequences of viruses. Full genome 
sequencing can be done fragment by fragment, but that is a very laborious 
process. So now it is done with various deep-sequencing platforms. DNA is 
broken up randomly into numerous small segments, which are then 
sequenced. Multiple overlapping reads for the target DNA are obtained by 
performing several rounds of this fragmentation and sequencing process. 
Dedicated computer programs are used to assemble the overlapping ends 
of different reads and to collate all sequence information into a continuous 
viral genome sequence.
Microarray
In DNA microarray, a collection of specific DNA molecule stretches is 
printed on a solid surface, on which DNA isolates from test samples are 
incubated. The underlying principle is that hybridization occurs between 
two DNA strands due to hydrogen bonds forming between complementary 
nucleotide base pairs. Once unbound DNA fragments have been removed 
by washing, only strongly paired strands will remain hybridized. This 
hybridization is made visible by fluorescent labelling sequences that bind 
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to a probe sequence. A signal is subsequently generated that depends on the 
hybridization conditions, such as temperature and washing after 
hybridization. The fluorescent signal can be read using a laser microscope 
and analyzed using a dedicated computer program. This DNA-on-a-chip 
method can be used to test several hundred viral DNA sequences 
simultaneously. The method is fast but not particularly cheap, and it relies 
on known sequences printed on the chip. 
Metagenomics
Early viral genome sequencing relied on cultured viruses and cloned DNA. 
Now “shotgun” or PCR-directed, high-throughput sequencing are used to 
obtain largely unbiased samples of all genes from all viruses in a sample. 
This metagenomics approach, in which genetic material is recovered directly 
from samples, can reveal previously unobserved diversity and provide 
important information on virus evolution. In infectious disease research, 
metagenomics techniques are attractive because they allow all viruses in a 
clinical sample to be captured using a single protocol. However, this 
approach still requires standardization and validation. Furthermore, 
appropriate bioinformatics analysis is needed in all cases to cope with the 
vast amounts of data generated. Laboratories have developed different 
workflows, depending on their primary goals for using metagenomics: for 
example, virus discovery, diagnostics, surveillance and evolutionary studies. 
Metagenomics studies have revealed trillions of different viruses, especially 
RNA viruses. Most of these new viruses are only known from sequence data. 
Only a few of these new viruses will ever be characterized biologically, and 
most of them may never be directly linked to biological agents, Nevertheless, 
including all sequences that may represent existing viruses in our 
classification system is important for research into the ecology, history and 
impact of the global virome. 
CRISPR-Cas
A major recent development in molecular biology is the powerful CRISPR-
Cas technology. It allows us to alter DNA sequences easily and modify gene 
function. The acronym CRISPR (Clustered Regularly Interspaced Short 
Palindromic Repeats) refers to unusual virus-derived, nucleic acid sequences 
that help protect organisms by identifying attacking viruses and destroying 
them. In short, organisms like bacteria, use CRISPR-derived RNA (crRNA), 
which binds to a complementary DNA target, to direct the protein Cas9 
(“CRISPR-associated”), an enzyme that cuts foreign strands of DNA. In 
nature, this system is used by bacteria to destroy viruses. Now, however, it 
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has been developed into a laboratory system for gene editing. In such a 
system, the DNA is cut, and then specific sequences of nucleotides are 
inserted in the gaps, thus modifying the genome as desired. 
In 2018, several studies detailed the use of CRISPR for diagnostic purposes. 
Assays are described in which activation of the guide RNA by a 
complementary sequence is followed by indiscriminate cleaving of 
fluorescent ssRNA or ssDNA probes by Cas13 and Cas12a enzymes 
respectively. This fluorescent signal can be made visible using isothermal 
amplification. These are highly promising developments for diagnostics 
because such CRISPR-Cas based assays are sensitive and specific, and can be 
performed directly on clinical samples as a single reaction without the need 
for much equipment. 
Viromes, Microbiomes 
Thanks to the latest sequencing techniques, we can now study the 
complete virome, the whole virus community of different ecosystems. 
Humans and animals are occupied by large collections of microorganisms. 
Viruses are even more abundant than bacteria, and mammalian viromes 
consist of trillions of viruses that are present on and inside the body. These 
can be viruses that infect humans or animals, but also viruses ingested via 
food. Most of these viruses do not cause disease, but many infect bacteria 
that live inside the body or on body surfaces. Despite the abundance of 
viruses, we know little about what they do. We know that viruses can be 
important pathogens in humans and that viruses of bacteria, called 
bacteriophages, can kill bacteria. We combat infectious viruses of humans 
and animals. Research on pathogenic bacteria is increasingly studying how 
we can use phage therapy to combat bacterial infections in humans. 
However, this research only covers a small proportion of the entire viral 
community. Recent studies indicate that the diverse communities of 
viruses in our intestinal tract, for example, have a host-microbe interaction 
relationship with both beneficial and detrimental outcomes for the host. An 
interesting research question in this respect is whether the virome could be 
used as a sensitive marker of alterations in a host’s health status. 
Detecting and combatting pathogenic viruses
Within Wageningen Bioveterinary Research, these innovative molecular 
detection and characterization methods have been implemented, optimized 
and combined into a workflow for virus discovery. The aim is to detect 
pathogenic viruses in animal disease cases of unexplained aetiology at an 
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early stage so that we are better prepared for new and emerging viruses. 
Different molecular techniques with or without prior knowledge of the 
genome sequences of the targeted virus are combined in flow charts of 
analytical methods to search for pathogenic viruses. Regular streams of test 
materials have been organized with the Netherlands Animal Health Service 
(GD Deventer) and the Utrecht University Wildlife Health Centre (DWHC). 
Large numbers of different types of samples from acutely diseased livestock 
or wildlife are analyzed in this diagnostic pipeline. Depending on the disease 
history, we usually start with targeted DNA/RNA extraction and processing, 
followed by PCR and microarray screening. Positive response samples are 
first characterized by DNA/RNA sequencing and compared with sequences 
available in databases. Next, they are tested using specific classical laboratory 
methods, which are still indispensable for biological characterization. 
Metagenomic analyses are then performed to try to catch all viruses for 
which no prior sequence information is available. Ultimately, however, we 
will still have to rely on current information in databases to establish whether 
detected sequences represent potentially pathogenic agents. As indicated, 
sequence analysis is followed by in vitro inoculations to characterize the virus 
further and elucidate its pathogenic potential. Experimental infection studies 
in animals can also be very helpful in establishing the clinical disease 
potential of a new virus. However, for ethical reasons this should only be 
done if really needed, for example, to generate research materials in the case 
of a new potentially highly pathogenic virus.
Virus Discovery Workflow, Wageningen Bioveterinary Research.
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Epidemiological studies are the first approach used to determine whether a 
newly detected pathogenic virus is associated with clinical disease. In the case 
of a severe acute disease outbreak, rapid disease risk evaluation, using the 
information available in an early stage of a disease outbreak, is important. 
Early evaluation of the public health risks is a priority issue. As more data is 
generated, this can be used to assess transmission rates and the potential for 
relevant control options. That can be realised by building statistical and 
mathematical models based on host range, transmission routes, disease 
reproduction ratio, et cetera. Quantitative epidemiology studies and 
modelling can be used to assess the effects of interventions. Subsequently, it 
can be evaluated if these outcomes can be extrapolated to new situations and 
used to design effective prevention and control strategies.
Virome studies
A relatively new field of research is the generation of metagenomic data of 
viral infections to quantitatively study the epidemiology of viral diseases. 
Livestock and wildlife viromes are detected and characterized using deep 
sequencing followed by computational approaches for epidemiological 
analyses. Specific viruses can cause disease, but changes in viromes within 
body compartments of animals may be associated with disease too. Virus 
identification by metagenomics approaches (metaviromics in short) together 
with epidemiologic analyses can be applied to study virus evolution, disease 
associations and disease transmissions. Subsequently, disease modelling can 
be done and disease risk assessments made.
Schmallenberg virus detected and controlled 
At our institute, the discovery of the Schmallenberg virus in Dutch cattle and 
sheep in 2011 is a fascinating example of novel molecular technologies used 
for virus discovery. In September of that year, a marked reduction in milk 
yield in dairy cattle was observed on several farms in the Netherlands and 
Germany. Pooled blood samples from the affected farms were tested using 
novel molecular approaches. A novel virus was traced by the Friedrich 
Loeffler Institute using metagenomic analyses. The new virus was named 
Schmallenberg virus (SBV) after the town of Schmallenberg where the first 
positive samples came from a dairy farm. Schmallenberg virus is most 
closely related to viruses of the Sathuperi species, a Simbu serogroup virus 
within the Orthbunyavirus family. This Schmallenberg virus infection was 
the first known outbreak caused by a member of the Simbu serogroup in 
Europe. Simbu viruses like Akabane virus are known to induce 
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malformations if the embryo or foetus is transplacentally infected during a 
vulnerable period. Immediately after the identification of this new RNA 
sequence, diagnostic methods were developed and implemented by the 
Friedrich Loeffler Institute and our group in Lelystad. Malformations that 
could definitely be attributed to Schmallenberg virus infection were 
observed from December 2011 onwards in stillborn or new-born lambs, 
calves and goat kids, which were usually born at term. The first 
Schmallenberg-virus-induced malformed lambs were confirmed in the 
Netherlands. The main pathological findings induced by Schmallenberg 
virus were identical to the changes described for severe Akabane virus 
infections: bent limbs, fixed joints, twisted neck and spine, short jaw and 
various malformations of the brain, cerebellum and spinal cord.
As the Simbu serogroup of viruses contains several medically relevant 
zoonotic viruses, such as Aino virus and Shuni virus, the emergence of 
Schmallenberg virus triggered a joint veterinary and public health response 
in the Netherlands to address the possible consequences for human health. 
In a close collaboration between Wageningen Bioveterinary Research and the 
National Institute for Public Health and the Environment in the Netherlands, 
serologic testing with a virus neutralization test was performed to evaluate 
immunologic responses in exposed people. Fortunately, none of the study 
subjects showed serologic evidence of Schmallenberg virus infection, 
Schmallenberg virus, Electron Microscopy (EM) image. © by H. Granzow, FLI, Germany.
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indicating that the risk of infection through contact with contaminated 
materials is minimal. Given the high seroprevalence of Schmallenberg virus 
in affected herds, the lack of any evidence for zoonotic transmission suggests 
that the public health risk for Schmallenberg virus is absent or extremely 
low. This was a major relief at the time and an excellent example of 
veterinary health and public health cooperation. 
Following the detection and characterization studies, we did a lot of research 
on Schmallenberg virus control and the development of effective vaccines. 
Since 2012, several vaccine products have become commercially available. 
Therefore, farmers can now vaccinate their sheep and cattle against the disease.
At our institute, research on the Schmallenberg virus has continued in the 
Zoonoses Anticipation and Preparedness project. This project aims to design 
new manufacturing processes for delivering effective control tools, such as 
vaccines and antibodies. These should enable a swift response to major new 
emerging zoonotic infectious disease threats in Europe and throughout the 
world. Schmallenberg virus is a prototype virus in this project. Jeroen 
Kortekaas is the principal investigator on this topic for Wageningen 
Bioveterinary Research.
Towards a Global One Health approach
A second important health concept in medicine is the “Global Health” 
concept. In the 21st century, the term “Global Health” has replaced earlier 
terms such as “international health” and “tropical medicine”. Global Health 
refers to health issues that concern many countries and is influenced by 
transnational determinants, such as climate change or urbanization. So here 
“Global” refers not just to the location of problems but also their scope. 
In 2009, in a publication in The Lancet, Jeffrey Koplan proposed defining 
“Global Health” as ‘the area of study, research, and practice that prioritizes 
improving health and achieving equity in health for all people worldwide. 
Global health emphasizes transnational health issues, determinants, and 
solutions. It involves many disciplines within and beyond the health 
sciences, promotes interdisciplinary collaboration, and is a synthesis of 
population-based prevention with individual-level clinical care.’ 
Infectious diseases in biological systems are dynamic: new infectious 
diseases will appear as infectious agents that contaminate and replicate in all 
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biological systems. An example of this is hepatitis E in fecally contaminated 
drinking water in refugee camps in Africa. New variants of viruses, like HIV, 
may emerge that are no longer controlled by the vaccines or antivirals 
applied in the population. Past experiences in infectious disease control 
demonstrate that a single set of measures is insufficient for a single disease. 
We need to do more than build a sewage system or provide just vaccines, for 
example. Infectious diseases should not only be considered from a bio-
medical perspective, but also in relation to the natural environment and its 
anthropogenic influences. A systems approach should preferably be used in 
which positive and negative factors for transmission and disease spread are 
taken into account. This can be defined as a “Global one health approach”: 
‘The combined effort of multiple disciplines to improve the health of 
humans, animals and plants within sustainable ecosystems at the global 
level by using an integrated systems approach to come to transnational and 
global policy, research and practices.’
On a global scale, eradication of infectious diseases is a goal of international 
organizations: the WHO for human medicine, the FAO and OIE for 
veterinary medicine, and the FAO for plant diseases. Cases of viral disease 
eradication, smallpox and rinderpest, are landmark achievements. 
Unfortunately, however, this list is not very long. Initially, eradication of a 
disease is often attempted, especially when the disease has severe 
consequences and mitigating measures, for example, vaccination, are 
scarcely possible. Later on, one or more mitigation options may become 
available. Then the aim will be to prevent the disease using a combination of 
eradication and mitigation strategies. 
This is how Ebola was dealt with in Africa. During the 2014-2016 outbreak in 
West Africa, the initial focus was on biocontainment and eradication. Later 
on, newly developed vaccines were applied, and finally, the combined 
efforts led to the disease’s eradication. In the current outbreak in Congo, the 
need to consider multiple factors to control the disease has once again 
become clear. The Ebola vaccine is proving highly effective, but distrust of 
health workers, skepticism of the disease’s existence or origin, and attacks on 
medical facilities are frustrating progress.  
Wageningen University investment theme “Global One Health”
In 2015, we started the Wageningen University and Research investment 
theme “Global One Health”. This theme was initially coordinated by Willem 
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Takken and I, and later on, Marcel Zwietering took over Willem Takken’s 
role. In just three years, twelve multidisciplinary research projects were 
started and successfully completed within this research theme. In all 
projects, there was a cooperation between a Wageningen Research unit and a 
Wageningen University department. A core group with representatives from 
all departments working on health research was formed, which acts as the 
research steering committee of the theme. Primary research outcomes 
included analyses of socioeconomic factors influencing the emergence of 
new zoonotic infection outbreaks, assessments of the risks of antimicrobial 
resistance in manure applied on crop fields, and analyses of the gut 
microbiome of virus-transmitting insects. With the theme research group, we 
have organized annual research symposia and several successful workshops, 
and the theme has also acted as a generator for several new projects in the 
field of One Health. I will discuss several of these later. 
In 2018, we established an international Global One Health network with 
three other top-ranked agricultural universities: University of California in 
Davis, USA, Nanjing Agricultural University in China and Massey 
University in New Zealand. This network enables PhD exchanges, and we 
are currently working on a Global One Health cooperative research 
programme for this network.
Determinants of Global One Health and Their Interactions.
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Netherlands Centre for One Health
The Netherlands Centre for One Health (NCOH) is an important national 
collaboration to tackle the global risks of infectious diseases. It is a network 
of academic research institutes in the Netherlands, which commits to 
creating durable solutions for major infectious disease challenges using an 
integrated One Health approach. NCOH was founded by Wageningen 
University and Utrecht University in February 2016. It has one common 
Strategic Research Agenda with four complementary Strategic Research 
Themes: Emerging Infectious Diseases Preparedness, Tackling Antimicrobial 
Resistance, Smart and Healthy Farming, and Healthy Wildlife and 
Ecosystems. 
Dick Heederik of Utrecht University chairs the NCOH executive board. As 
principal investigator of Wageningen University and Research, I collaborate 
with the different theme leaders within the network. Recently, under the 
coordination of Marion Koopmans, of Erasmus University Rotterdam, we 
submitted a large research proposal in response to the “Dutch National 
Research Agenda” call. This proposal focusses on new emerging insect-
transmitted viruses and comprises research ideas of several Wageningen 
University colleagues, including Mart de Jong, Monique van Oers, Gorben 
Pijlman, Sander Koenraadt, Fred de Boer and Jeroen Kortekaas. 
Netherlands Centre for One 
Health (NCOH) Research 
Themes.
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The One Health European Joint Programme (One Health EJP)
A European example of implementing the One Health concept is the One 
Health European Joint Programme. This has realized a partnership between 
38 acclaimed food, veterinary and medical laboratories and institutes across 
19 Member States in Europe. In line with the “Prevent-Detect-Respond” 
concept, the main focus of this 5-year EU programme is to reinforce 
collaboration between institutes by enhancing transdisciplinary cooperation 
and integration of activities. This will be achieved by developing dedicated 
Joint Research Projects (JRPs) and Joint Integrative Projects (JIPs), and 
establishing education and training in the fields of Foodborne Zoonoses 
(FBZ), Antimicrobial Resistance (AMR) and Emerging Threats (ET) is 
established.
Most of the 38 partner institutes have reference responsibilities, representing 
a sustainable framework for an integrated research community. By 
collaborating more closely, the EJP partners can align their approaches, 
increase their knowledge and improve epidemiological studies and risk 
assessments. The ultimate goal is to provide risk managers with suitable 
prevention and control strategies and the best tools for intervention 
measures. Within this EJP project, Wageningen Bioveterinary Research 
collaborates with many European research institutes in a growing number of 
internal research projects as well as integrative projects. Half of the funding 
comes from the EU and half from national governments. On the national 
side, research details are discussed with the Ministry of Health, Welfare and 
Sport and the Ministry of Agriculture, Nature and Food. Within Wageningen 
Bioveterinary Research this is also tuned with Willie Loeffen, Head of the 
Statutory Tasks Unit for Transmissible Animal Diseases. As a member of the 
project management board, I act as the point of contact for Wageningen 
Bioveterinary Research and assist in developing and realizing all projects we 
are involved in.
Chair research and education themes
In this chair, I aim to work on at least three themes for research and 
education: 1. Detection and characterization of new emerging viruses, 2. 
Infection and epidemiology of zoonotic viruses, and 3. Global One Health.
Within the theme “Detection and characterization of new emerging viruses”, 
I will continue my research on the preparedness for new and emerging 
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viruses and constantly try to detect pathogenic viruses in animal disease 
cases of unexplained aetiology at an early stage. This work will result in a lot 
of new data about circulating viruses and related research objectives. So 
there will be plenty of relevant topics for master or PhD students to work on 
a thesis at Wageningen Bioveterinary Research in Lelystad, such as data 
evaluation, additional laboratory testing or epidemiological studies. 
Metagenomics will be applied to study viromes within different livestock 
species. A study on the pig gut microbiome will be realized as part of an 
emerging risks study within the new Wageningen Research theme “Healthy 
and Safe”. Current and new omics analyses will be used to try to assess host 
immunity and expected susceptibility to new virus infections. Together with 
the group of Alex Bossers, we will start a PhD project on metagenomic 
aspects related to goat farms in the Netherlands. This study is part of the 
VGO III project (“Veehouderij en Gezondheid Omwonenden” III/”Health of 
residents living nearby livestock farms”) project. 
The theme “Infection and epidemiology of zoonotic viruses” includes 
foodborne viruses and our research in this theme will primarily focus on 
hepatitis E virus. Basic and applied research will assess the public health 
threats and how to control such a zoonotic virus in the food production 
chain. Two PhD students in our group are currently working on hepatitis. 
Renate Hakze is studying the infectivity of circulating hepatitis E viruses in 
the Netherlands. Marina Meester is studying biosecurity options for 
hepatitis E virus in pig farms in cooperation with Arjan Stegeman and Tijs 
Tobias from Utrecht University. Pulled by Marcel Hulst and Tinka Jelsma 
we continue our work on inactivation of viruses in the food and feed 
production chains.
As part of the first phase course “Health Issues in Daily Life; a Bèta-Gamma 
Approach” of the Department of Social Sciences, I will continue my lectures 
on the hazards of zoonotic and foodborne viruses. I aim to work closely with 
the Chair Group Virology of professor Monique van Oers, and other 
Wageningen University groups as appropriate, to develop and implement 
courses related to virology and to realize viral zoonoses research. The 
stability and persistence of viruses in mammalian host populations and their 
environment will be a topic of interest for education within this theme. 
In the “Global One Health” theme, I will continue to stimulate 
interdisciplinary research cooperation. A primary research objective is to 
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further develop a coherent vision and a systems approach for 
multidisciplinary research. This will build on and combine current expertise 
fields in Wageningen to genuinely integrate scientific responses to Global 
One Health challenges. 
We have developed a “Global One Health” Summer Course in Wageningen 
together with Henk Hogeveen and the support of many others. It will be 
given for the third time this year and in future years subject to demand. Led 
by Sander Koenraadt and supported by Marcel Zwietering and Marcel 
Verweij, we have submitted a proposal as the Global One Health Core Group 
for a bachelor minor on “Global One Health”. In short, the learning 
outcomes include: a) Understand basic concepts in health research, b) 
Understand connections and conflicts of health research, c) Ability to 
implement a multidisciplinary approach in health research.
In all three themes, a significant part of my time will be devoted to MSc and 
PhD education. I will focus on supervising the writing of MSc and PhD 
theses and supporting the necessary training for this. MSc students and PhD 
students will have the option of an internship for laboratory training at 
Wageningen Bioveterinary Research under my supervision. 
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Conclusion
As I come to the end of this inaugural address, I conclude that emerging 
viral diseases can have a huge impact on society. Preparedness for and 
control of new and emerging viral diseases is very challenging. It needs to be 
addressed through the collaboration of all health-related research disciplines 
using a multidisciplinary Global One Health approach. A growing number 
of innovative methods are being developed in infectious disease research. 
We should all use these as much as possible to prevent and control emerging 
infectious diseases both now and in the future. 
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Afsluiting
Aan het einde van deze inaugurele rede wil ik graag een aantal mensen 
bedanken. Maar eerst wil ik zeggen dat de discussie over het gebruik van de 
Nederlandse taal in het onderwijs mij niet is ontgaan. Ik ben niet van mening 
dat het Nederlands uit het onderwijs moet verdwijnen. Ik ben wel van mening 
dat wetenschappelijk onderzoek internationaal gedeeld moet worden, en dat 
onderzoek en hoger onderwijs met elkaar verbonden dienen te zijn. Ook het 
onderwijs wordt daarmee meer internationaal en de taal van 1e keuze is het 
Engels. Ik heb daarom zonder meer gehoor gegeven aan de wens van de 
Universiteit om deze inaugurele rede uit te spreken in het Engels.
Dan nu het dankwoord: Arthur Mol, Rector Magnificus en Louise Fresco 
Voorzitter van de Raad van Bestuur van de Wageningen Universiteit wil ik 
bedanken voor het mogelijk maken mijn aanstelling als bijzonder hoogleraar 
bij Wageningen Universiteit. Ludo Hellebrekers, directeur van Wageningen 
Bioveterinary Research en Martin Scholten directeur van de Animal Sciences 
Group van Wageningen Research wil ik bedanken voor het in mij gestelde 
vertrouwen. De goede samenwerking met jullie beide heeft een belangrijke 
bijdrage geleverd aan het ontwikkelen van de onderzoekdisciplines 
waarbinnen ik actief ben.  Ik hoop dat we dat in de komende jaren kunnen 
voortzetten. 
Mart de Jong leerstoelhouder quantitatieve veterinaire epidemiologie wil ik 
bedanken voor de ruimte die ik heb gekregen binnen zijn leerstoelgroep. Ik 
heb veel bewondering voor je enorme mathematische en epidemiologische 
kennis. Samen met collega hoogleraar Ynte Schukken en de andere 
medewerkers van de groep zijn we enthousiast begonnen aan een mooie 
samenwerking met kerndisciplines epidemiologie en infectieziekten. Ik heb 
er veel vertrouwen in. Met de andere leerstoelhouders binnen de Animal 
Sciences Group zijn er inmiddels ook samenwerkingen. Ik ben er van 
overtuigd dat we dat in de komende jaren kunnen uitbreiden. 
Mijn promotores Professor Arie Brand en Professor Jan van Oirschot ben ik 
dankbaar voor de inleiding in de wetenschap en de liefde voor de virologie. 
Ik denk nog regelmatig terug aan de adviezen die jullie mij gegeven hebben.
Mijn collega’s van Wageningen Bioveterinary Research in Lelystad wil ik 
bedanken voor de vele dingen die ze in de afgelopen jaren voor mij gedaan 
hebben. Van reizen boeken, financiële overzichten en video-opnames tot 
ingewikkelde wetenschappelijke experimenten. Teveel om op te noemen. 
Zonder jullie had ik hier nooit kunnen staan. 
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Mijn contactpersonen bij opdrachtgevers Ministeries van Landbouw 
Natuurbeheer en Voedsel, en Volksgezondheid Welzijn en Sport, 
Christianne Bruschke, Frouke de Groot, Annemarie Bouma, Francoise 
Divanach, Yvonne de Nas en Stephanie Wiessenhahn bedank ik voor alle 
nuttige besprekingen over onderzoek door de jaren heen. 
Virussen en vooral het onderzoek daarnaar is niet aan grenzen gebonden en 
Global One Health’’ is per definitie een wereldwijde uitdaging. Dat betekent 
dat ik samenwerk met heel veel buitenlandse onderzoekers en 
onderzoeksinstituten. Ik ben lid van diverse internationale organen, 
commissies en besturen. Al de collega’s die ik daarbij tegenkom ben ik 
dankbaar voor de vele vruchtbare samenwerkingen. 
Mijn ouders wil ik bedanken voor het feit dat ze mijn studie mogelijk 
gemaakt hebben. Mijn vader kan dit moment helaas niet meer meemaken, 
het zou hem vervuld hebben met veel trots. Ik ben blij dat mijn moeder, mijn 
broer en al mijn zussen hier allen aanwezig zijn. Dat onderstreept de goede 
familierelatie.
‘Last but not least’ mijn gezin. Moniek bedankt dat je me altijd de ruimte 
hebt gegeven om me in te zetten voor mijn werk, en voor het feit dat je altijd 
graag bereid was om kritisch te kijken naar de communicatie over ons 
onderzoek vanuit het perspectief van het publiek. Loran met jou deel ik de 
liefde voor de sport. Ik hoop dat we de doelpunten van Ajax nog vaak 
kunnen bespreken. Jarne, met jou deel ik de liefde voor Europa. Het zou me 
niets verbazen als we elkaar met werk in Brussel nog eens tegenkomen. We 
zien elkaar lang niet elke dag meer maar jullie drieën zijn mijn thuis. Of het 
nou met vakantie is of met een feestje of een etentje, Ik hoop dat we nog heel 
veel quality time met elkaar kunnen beleven. 
Tenslotte, in gedachte nog even terug naar die bewuste 12 maart 2003. Sinds 
het uitbreken van SARS, zijn er heel veel nieuwe ontwikkelingen in de 
biomedische wetenschap. Met de overtuiging dat alle gezondheid-
gerelateerde wetenschappen met elkaar moeten samenwerken in een Global 
One Health benadering, en dat disciplines binnen de virologie nauw met 
elkaar verbonden moeten zijn, zullen we in de toekomst beter voorbereid 
zijn op nieuwe bedreigende virusziekten.
Ik heb gezegd.
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'New emerging infectious disease outbreaks are complex events 
that can have a huge impact on society. Preparedness for and 
control of new and emerging viruses is very challenging. For 
prevention and control of emerging diseases, collaboration of all 
health-related research disciplines will be needed, using a 
multidisciplinary Global One Health approach. A growing number 
of innovative molecular methods are being developed in infectious 
disease research. We should all use these as much as possible to 
prevent and control new and emerging viruses effectively, both 
now and in the future'
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